Etilefrine: A Novel Treatment for Refractory, Life-Threatening Chylothorax in the Newborn
There are few evidence-based treatment options for chylothorax in newborns. We report on 5 cases of preterm newborn infants who received drainage and continuous etilefrine infusion for clinically significant, refractory chylothorax. Irrespective of the cause of the effusion, etilefrine infusion was associated with a clear decrease in chylous output within 2 to 4 days of initiation with heart rates and blood pressures maintained within the age-normal limits.
Authors
- Caroline Chopinet
- Sixtine Gilliot (ORCID: https://orcid.org/0000-0001-7944-7443)
- Kévin Le Duc (ORCID: https://orcid.org/0000-0003-4970-4458)
- Bertrand Décaudin (ORCID: https://orcid.org/0000-0001-8267-5594)
- Laurent Storme (ORCID: https://orcid.org/0000-0002-4266-0336)
- Mohamed Riadh Boukhris (ORCID: https://orcid.org/0000-0002-1597-0320)
- Pascal Odou
Institutions
- Université de Lille (FR)
- Lille’s Cardiology Hospital (FR)
Publication Details
- Journal
- PEDIATRICS
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1542/peds.2024-069683
- Citations
- 1
- Primary Topic
- Lymphatic Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01